The experimental Alzheimer’s disease treatment ELND005 has resulted in the death of nine patients. These deaths occurred during high-dose trials of this potential Alzheimer’s treatment.
Irish-based company Elan Corp has discontinued the high-dose trials of this experimental Alzheimer’s treatment.
As part of the Phase II trials, Alzheimer’s patients were receiving the experimental drug treatment twice a day. Doses of 1000mg and 2000mg of the Alzheimer’s drug treatment ELND005 were given to some patients, while others received 250mg and placebos. The Phase II trial of this experimental Alzheimer drug treatment will continue at the lower dosage.
The company has indicated that all patients enrolled in the high-dose trials will be immediately withdrawn from the trial. However a company spokesperson indicated that trials of this Alzheimer’s disease treatment will continue at the lower doses stating “Today’s decision speaks to our strong commitment to patient safety while allowing for the continued evaluation of ELN005 at the 250mg dose.”
Elan Corp has other Alzheimer’s disease treatments based on its Alzheimer’s Immunotherapy Program and has entered into a deal with Johnson & Johnson to continue the development of its Alzheimer’s drugs.
{ 1 trackback }
{ 0 comments… add one now }